ARC
RIGL icon

Absolute Return Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Absolute Return Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,637
Closed -$102K – 1350
2014
Q1 		$102K Buy
+2,637
New +$94K ﹤0.01% 1138

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Absolute Return Capital's RIGL Position: Q2 2014 in Review

Absolute Return Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2014, closing a stake of 2,637 shares — an estimated $102K sold.

Absolute Return Capital first reported a position in RIGL in Q1 2014 and held it in 1 quarter. The position peaked at $102K in Q1 2014. 103 funds tracked by Wall St. Rank hold RIGL as of Q2 2014.

  • Absolute Return Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Absolute Return Capital sold 2,637 Rigel Pharmaceuticals shares in Q2 2014, an estimated $102K.
  • Absolute Return Capital first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Absolute Return Capital's Rigel Pharmaceuticals position peaked at $102K in Q1 2014.
  • 103 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.